General Information of Drug (ID: DMVD702)

Drug Name
1,2,3,4,5,6-hexabromocyclohexane Drug Info
Synonyms
1,2,3,4,5,6-Hexabromocyclohexane; 1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694
Indication
Disease Entry ICD 11 Status REF
Liver cancer 2C12 Investigative [1]
Cross-matching ID
PubChem CID
74603
ChEBI ID
CHEBI:93940
CAS Number
CAS 1837-91-8
TTD Drug ID
DMVD702

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Janus kinase 2 (JAK-2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Momelotinib DMF98Q0 Myelofibrosis 2A20.2 Approved [3]
Baricitinib DM4ONW5 Rheumatoid arthritis FA20 Approved [4]
Ruxolitinib DM7Q98D Essential thrombocythemia 3B63.1Z Approved [5]
Pacritinib DM1T6ZN Myelofibrosis 2A20.2 Approved [6]
Fedratinib DM4ZBK6 Myelofibrosis 2A20.2 Approved [7]
ITF2357 DMFZBNE Duchenne dystrophy 8C70 Phase 3 [8]
XL019 DMJ6F5C Solid tumour/cancer 2A00-2F9Z Phase 3 [8]
Cerdulatinib DMSCR2H B-cell lymphoma 2A86 Phase 2 [9]
CTP-543 DM3SYOK Alopecia ED70 Phase 2 [10]
INCB039110 DMD9RV3 Malignant neoplasm 2A00-2F9Z Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Janus kinase 2 (JAK-2) TTRMX3V JAK2_HUMAN Inhibitor [2]

References

1 Leptin increases the expression of the iron regulatory hormone hepcidin in HuH7 human hepatoma cells. J Nutr. 2007 Nov;137(11):2366-70.
2 Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation]. J Med Chem. 2005 Apr 7;48(7):2526-33.
3 Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.Leukemia.2015 Mar;29(3):741-4.
4 Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
5 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
6 National Cancer Institute Drug Dictionary (drug id 609888).
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
8 Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
9 Company report (Portola Pharmaceuticals)
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048).